engleski

Efficacy and tolerability of multiple doses of Lu AA21004 in an 8-week treatment of adults with major depressive disorder.

The results of this phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial of Lu AA21004 in 560 adult patients with MDD, showed significant reduction in Hamilton Depression Rating Scale (HAM-D24) scores for all Lu AA21004 treatment groups (1 mg, 5 mg, 10 mg) compared with placebo after 8 weeks of treatment (p<0.0001). The most common treatment emergent adverse events (i.e., those reported by at least 10 percent of Lu AA21004 patients, and twice the rate of placebo) were nausea, headache and dizziness.

Lu AA21004

nije evidentirano